ライフサイエンスコーパス: drug repurposing

1 s on compound MoA and potential insights for drug repurposing.

2 then be targeted by specific therapies) and drug repurposing.

3 e drugs, and providing new opportunities for drug repurposing.

4 -approved drug, is a promising candidate for drug repurposing.

5 ch for both novel disease gene discovery and drug repurposing.

6 knowledge base in disease gene discovery and drug repurposing.

7 derstanding of disease etiology and in rapid drug repurposing.

8 is important for computational approaches to drug repurposing.

9 ns, and opportunities for drug discovery and drug repurposing.

10 sms and can be used to improve computational drug repurposing.

11 et the need for improved cancer treatment is drug repurposing.

12 Bioinformatics drug repurposing analyses with the gene expression biosi

13 signature, which was used for computational drug repurposing analysis.

14 bioinformatics-driven discovery roadmap for drug repurposing and development in overcoming resistanc

15 s that offer unprecedented opportunities for drug repurposing and the detection of adverse effects.

16 ng gene expressions with drugs/compounds for drug repurposing and translational research.

17 arising from off-target effects, comment on drug repurposing, and introduce approaches to the comput

18 This in-silico drug repurposing approach suggested several compounds th

19 By using an "in silico drug repurposing" approach and by validating our predict

20 Following a "drug repurposing" approach, we tested anti-trypanosomal

21 Further cancer drug repurposing approaches reveal that NVP-AUY922 downr

22 Outputs help to develop hypotheses about drug repurposing as well as potential side effects.

23 Drug repurposing bioinformatics analyses identified the

24 Our data identify GA as an attractive drug repurposing candidate to treat infections with Gram

25 ilepsy, suggesting they will help prioritize drug repurposing candidates.

26 cal guidelines, many more could benefit from drug repurposing, considering compounds at various stage

27 rch and development of new drugs, a focus on drug repurposing could alleviate this problem by reposit

28 Overall, drug repurposing could become increasingly important as

29 models, case reports, and clinical trials of drug repurposing efficacy in allergic disease are review

30 on, anticipate adverse events, and assist in drug repurposing efforts.

31 esting that PPS is a promising candidate for drug repurposing for the treatment of alphavirus-induced

32 Genomics-based drug repurposing (GBR) offers the potential of savings i

33 e new classification can be used to generate drug repurposing hypotheses, using Alzheimers disease as

34 Our findings suggest that NRTIs are ripe for drug repurposing in P2X7-driven diseases.

35 e-wide association results in psychiatry for drug repurposing is an ongoing challenge.

36 urces that has been relatively neglected for drug repurposing is animal model phenotype.

37 Moreover, as drug repurposing is becoming an attractive drug discover

38 Drug repurposing is the application of approved drugs to

39 -approved drug-disease indication as well as drug-repurposing knowledge that is crucial for applying

40 ndrial ATP synthase disorders, we screened a drug repurposing library, and applied genomic and bioche

41 Drug repurposing of non-cancer drugs represents an attra

42 lico toolbox for drug target identification, drug repurposing, phenotypic screening, and side effect

43 We applied an in silico "drug repurposing" procedure for identification of nonste

44 Drug repurposing provides a potentially efficient soluti

45 Computation-based drug-repurposing/repositioning approaches can greatly sp

46 ther neurological conditions, we performed a drug repurposing screen of approximately 6,000 compounds

47 In a drug repurposing screen targeting CYP2J2, the human orth

48 In this study, we performed a novel drug-repurposing screening to identify Food and Drug Adm

49 Two recent drug repurposing screens identified ITZ as a promising a

50 d of drug repurposing, the implementation of drug repurposing still faces important financial and reg

51 in the context of clinical trials to develop drug repurposing strategies for patients with urgent med

52 By using a "drug repurposing" strategy, histone deacetylase inhibito

53 s, will have high potential in computational drug repurposing tasks.

54 These drug repurposing techniques have been successful in iden

55 earch is progressing rapidly in the field of drug repurposing, the implementation of drug repurposing

56 s iguratimod as a valuable new candidate for drug repurposing to MIF-relevant diseases, including mul

57 provides a workflow for pathway analysis and drug repurposing using GWAS results.

58 ofiles can be used to generate hypotheses of drug-repurposing, whereas positively correlated profiles